Macrogenics (MGNX) EBIAT (2016 - 2025)
Macrogenics (MGNX) has disclosed EBIAT for 14 consecutive years, with -$14.2 million as the latest value for Q4 2025.
- Quarterly EBIAT rose 8.21% to -$14.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$74.6 million through Dec 2025, down 11.43% year-over-year, with the annual reading at -$74.6 million for FY2025, 11.43% down from the prior year.
- EBIAT for Q4 2025 was -$14.2 million at Macrogenics, down from $16.8 million in the prior quarter.
- The five-year high for EBIAT was $57.5 million in Q2 2023, with the low at -$66.4 million in Q1 2022.
- Average EBIAT over 5 years is -$23.6 million, with a median of -$39.0 million recorded in 2021.
- The sharpest move saw EBIAT tumbled 2680.16% in 2021, then surged 239.14% in 2023.
- Over 5 years, EBIAT stood at -$58.0 million in 2021, then surged by 122.06% to $12.8 million in 2022, then crashed by 459.88% to -$46.1 million in 2023, then surged by 66.53% to -$15.4 million in 2024, then grew by 8.21% to -$14.2 million in 2025.
- According to Business Quant data, EBIAT over the past three periods came in at -$14.2 million, $16.8 million, and -$36.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.